Latest Information Update: 20 Mar 2017
At a glance
- Originator Eyenovia
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mydriasis
Most Recent Events
- 01 Nov 2016 Eyenovia completes a phase-II clinical trial in Mydriasis (In volunteers) in USA (Ophthalmic) (NCT02946125)
- 01 Oct 2016 Phase-II clinical trials in Mydriasis (In volunteers) in USA (Ophthalmic) (NCT02946125)